Tian P.,CAS Shanghai Institute of Organic Chemistry |
Dong H.-Q.,CAS Shanghai Institute of Organic Chemistry |
Dong H.-Q.,OSI Pharmaceuticals Inc. |
Lin G.-Q.,CAS Shanghai Institute of Organic Chemistry
ACS Catalysis | Year: 2012
Rhodium-catalyzed asymmetric arylation (RCAA) reactions provide one of the most straightforward and powerful ways to introduce aryl fragments in an enantioselective manner. The discovery of novel chiral ligands and catalytic systems is a major focus in generating optical chiralities for RCAA reactions. In the past decade, the chelating functionalities in ligands have been significantly expanded from traditional phosphorus to interesting diene, bissulfoxide, and their hybrids. Herein we highlight the research on these distinct families of chiral ligands and describe their applications in the RCAA of arylmetals to activated alkenes, aldehydes, ketones and imines, and RCAA-tandem reactions. © 2011 American Chemical Society.
AVEO Pharmaceuticals and OSI Pharmaceuticals Inc. | Date: 2012-04-25
The present invention provides diagnostic methods for assessing the EMT status of tumor cells, and for predicting the effectiveness of treatment of a cancer patient with an EGFR or IGF-1R kinase inhibitor, utilizing an EMT gene signature index score. The present invention further provides methods for treating patients with cancer that incorporate these methods.
OSI Pharmaceuticals Inc. | Date: 2013-05-23
A process for preparing a compound of formula (I) or a salt thereof: (I) wherein R1 is H or optionally substituted aryl or heteroaryl; comprising reacting 2,3-dichloropyrazine with a suitable diaryl imine followed by hydrolysis.
OSI Pharmaceuticals Inc. | Date: 2011-02-09
A method for determining whether to administer a therapeutically effective amount of a receptor tyrosine kinase-inhibiting drug for tumor treatment, by determining a glucose uptake response in the tumor of a mammal.
Pfizer and OSI Pharmaceuticals Inc. | Date: 2014-11-10
Processes and intermediates for the preparation of compounds of the Formula I and the pharmaceutically acceptable salts, prodrugs, solvates and hydrates thereof, wherein R